vs

Side-by-side financial comparison of ImmunityBio, Inc. (IBRX) and MEDALLION FINANCIAL CORP (MFIN). Click either name above to swap in a different company.

MEDALLION FINANCIAL CORP is the larger business by last-quarter revenue ($70.6M vs $38.3M, roughly 1.8× ImmunityBio, Inc.). MEDALLION FINANCIAL CORP runs the higher net margin — 17.3% vs -161.8%, a 179.1% gap on every dollar of revenue. On growth, ImmunityBio, Inc. posted the faster year-over-year revenue change (407.0% vs 25.4%).

ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing next-generation immunotherapies and vaccine candidates targeting multiple cancer types and infectious diseases. It operates mainly in the U.S. market, with core R&D segments including cell therapy, antibody therapeutics, and targeted vaccine platforms designed to enhance patient treatment outcomes.

Mahindra & Mahindra Financial Services Limited (MMFSL) is an Indian rural non-banking financial company headquartered in Mumbai. It is amongst the top tractor financers in India, with 1000+ offices across the country.

IBRX vs MFIN — Head-to-Head

Bigger by revenue
MFIN
MFIN
1.8× larger
MFIN
$70.6M
$38.3M
IBRX
Growing faster (revenue YoY)
IBRX
IBRX
+381.5% gap
IBRX
407.0%
25.4%
MFIN
Higher net margin
MFIN
MFIN
179.1% more per $
MFIN
17.3%
-161.8%
IBRX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
IBRX
IBRX
MFIN
MFIN
Revenue
$38.3M
$70.6M
Net Profit
$-61.9M
$12.2M
Gross Margin
99.0%
Operating Margin
-169.0%
29.3%
Net Margin
-161.8%
17.3%
Revenue YoY
407.0%
25.4%
Net Profit YoY
-4.7%
20.3%
EPS (diluted)
$-0.06
$0.50

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IBRX
IBRX
MFIN
MFIN
Q4 25
$38.3M
$70.6M
Q3 25
$32.1M
$58.7M
Q2 25
$26.4M
$62.6M
Q1 25
$16.5M
$63.0M
Q4 24
$7.6M
$56.3M
Q3 24
$6.1M
$53.3M
Q2 24
$51.0M
Q1 24
$53.3M
Net Profit
IBRX
IBRX
MFIN
MFIN
Q4 25
$-61.9M
$12.2M
Q3 25
$-67.3M
$7.8M
Q2 25
$-92.6M
$11.1M
Q1 25
$-129.6M
$12.0M
Q4 24
$-59.2M
$10.1M
Q3 24
$-85.7M
$8.6M
Q2 24
$7.1M
Q1 24
$10.0M
Gross Margin
IBRX
IBRX
MFIN
MFIN
Q4 25
99.0%
Q3 25
99.4%
Q2 25
99.5%
Q1 25
99.6%
Q4 24
Q3 24
Q2 24
Q1 24
Operating Margin
IBRX
IBRX
MFIN
MFIN
Q4 25
-169.0%
29.3%
Q3 25
-173.5%
33.2%
Q2 25
-269.8%
31.1%
Q1 25
-390.1%
32.1%
Q4 24
-919.0%
32.8%
Q3 24
-1314.3%
26.6%
Q2 24
24.3%
Q1 24
33.6%
Net Margin
IBRX
IBRX
MFIN
MFIN
Q4 25
-161.8%
17.3%
Q3 25
-209.8%
13.2%
Q2 25
-350.3%
17.7%
Q1 25
-784.9%
19.1%
Q4 24
-783.4%
18.0%
Q3 24
-1404.0%
16.1%
Q2 24
13.9%
Q1 24
18.8%
EPS (diluted)
IBRX
IBRX
MFIN
MFIN
Q4 25
$-0.06
$0.50
Q3 25
$-0.07
$0.32
Q2 25
$-0.10
$0.46
Q1 25
$-0.15
$0.50
Q4 24
$-0.08
$0.43
Q3 24
$-0.14
$0.37
Q2 24
$0.30
Q1 24
$0.42

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IBRX
IBRX
MFIN
MFIN
Cash + ST InvestmentsLiquidity on hand
$242.8M
$136.3M
Total DebtLower is stronger
$216.0M
Stockholders' EquityBook value
$-500.5M
$408.6M
Total Assets
$501.9M
$3.0B
Debt / EquityLower = less leverage
0.53×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IBRX
IBRX
MFIN
MFIN
Q4 25
$242.8M
$136.3M
Q3 25
$257.8M
$72.5M
Q2 25
$153.7M
$110.4M
Q1 25
$61.6M
$131.5M
Q4 24
$149.8M
$98.2M
Q3 24
$130.4M
$120.6M
Q2 24
$87.7M
Q1 24
$54.8M
Total Debt
IBRX
IBRX
MFIN
MFIN
Q4 25
$216.0M
Q3 25
$215.7M
Q2 25
$199.9M
Q1 25
$199.7M
Q4 24
$232.2M
Q3 24
$232.0M
Q2 24
$230.8M
Q1 24
$225.6M
Stockholders' Equity
IBRX
IBRX
MFIN
MFIN
Q4 25
$-500.5M
$408.6M
Q3 25
$-524.3M
$397.4M
Q2 25
$-570.7M
$389.9M
Q1 25
$-591.4M
$380.2M
Q4 24
$-489.1M
$370.2M
Q3 24
$-745.1M
$362.4M
Q2 24
$354.0M
Q1 24
$349.0M
Total Assets
IBRX
IBRX
MFIN
MFIN
Q4 25
$501.9M
$3.0B
Q3 25
$519.0M
$2.9B
Q2 25
$402.1M
$2.9B
Q1 25
$303.8M
$2.8B
Q4 24
$382.9M
$2.9B
Q3 24
$364.6M
$2.9B
Q2 24
$2.8B
Q1 24
$2.6B
Debt / Equity
IBRX
IBRX
MFIN
MFIN
Q4 25
0.53×
Q3 25
0.54×
Q2 25
0.51×
Q1 25
0.53×
Q4 24
0.63×
Q3 24
0.64×
Q2 24
0.65×
Q1 24
0.65×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IBRX
IBRX
MFIN
MFIN
Operating Cash FlowLast quarter
$-70.4M
$126.3M
Free Cash FlowOCF − Capex
$-71.3M
FCF MarginFCF / Revenue
-186.2%
Capex IntensityCapex / Revenue
2.4%
Cash ConversionOCF / Net Profit
10.35×
TTM Free Cash FlowTrailing 4 quarters
$-308.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IBRX
IBRX
MFIN
MFIN
Q4 25
$-70.4M
$126.3M
Q3 25
$-68.9M
$67.0M
Q2 25
$-79.7M
$-10.7M
Q1 25
$-85.9M
$36.3M
Q4 24
$-85.1M
$108.7M
Q3 24
$-98.8M
$24.6M
Q2 24
$27.6M
Q1 24
$32.3M
Free Cash Flow
IBRX
IBRX
MFIN
MFIN
Q4 25
$-71.3M
Q3 25
$-69.6M
Q2 25
$-80.8M
Q1 25
$-87.0M
Q4 24
$-87.3M
Q3 24
$-101.6M
Q2 24
Q1 24
FCF Margin
IBRX
IBRX
MFIN
MFIN
Q4 25
-186.2%
Q3 25
-217.2%
Q2 25
-305.9%
Q1 25
-526.9%
Q4 24
-1155.4%
Q3 24
-1663.2%
Q2 24
Q1 24
Capex Intensity
IBRX
IBRX
MFIN
MFIN
Q4 25
2.4%
Q3 25
2.3%
Q2 25
4.1%
Q1 25
6.8%
Q4 24
28.0%
Q3 24
45.7%
Q2 24
Q1 24
Cash Conversion
IBRX
IBRX
MFIN
MFIN
Q4 25
10.35×
Q3 25
8.63×
Q2 25
-0.97×
Q1 25
3.02×
Q4 24
10.72×
Q3 24
2.86×
Q2 24
3.89×
Q1 24
3.22×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons